TY - JOUR
T1 - Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins
AU - Rizwan, Shakila
AU - Boyd, Benjamin
AU - Rades, Thomas
AU - Hook, Sarah
PY - 2010
Y1 - 2010
N2 - Importance of the field: Self-assembling lipid-based liquid crystalline systems
are a broad and active area of research. Of these mesophases, the cubic phase
with its highly twisted bilayer and two non-intersecting water channels has
been investigated extensively for drug delivery. The cubic phase has been
shown to accommodate and control the release of drugs with varying physicochemical
properties. Also, the lipids used to prepare these delivery systems
are generally cheap, safe and biodegradable, making these systems highly
attractive. Early research investigating the potential of cubic phases as delivery
systems showed that several peptides or proteins entrapped within these
gel-based systems showed retarded release. Furthermore, entrapment within
the cubic phase protected the selected peptide or protein from chemical and
physical degradation with its native confirmation and bioactivity retained.
Areas covered in this review: In this review, the literature pertaining to the
delivery of various bioactives from cubic liquid crystalline phases is examined,
with a particular focus on peptides and proteins. The scope and limitations
of the cubic phases in this respect and the future of cubic liquid crystalline
systems as sustained delivery systems are highlighted.
What the reader will gain: The reader will be able to gain an understanding
of the properties of the bicontinuous cubic phase and how its structural
attributes make these systems desirable for sustained delivery of bioactives,
in particular peptides and proteins, but also how these same structural properties
have hindered progress towards clinical applications. Current strategies
to overcome these issues will also be discussed.
Take home message: The bicontinuous cubic phase offers great potential in
the field of peptide and protein delivery, but limited research in this area
precludes definite conclusions to its future in this respect.
AB - Importance of the field: Self-assembling lipid-based liquid crystalline systems
are a broad and active area of research. Of these mesophases, the cubic phase
with its highly twisted bilayer and two non-intersecting water channels has
been investigated extensively for drug delivery. The cubic phase has been
shown to accommodate and control the release of drugs with varying physicochemical
properties. Also, the lipids used to prepare these delivery systems
are generally cheap, safe and biodegradable, making these systems highly
attractive. Early research investigating the potential of cubic phases as delivery
systems showed that several peptides or proteins entrapped within these
gel-based systems showed retarded release. Furthermore, entrapment within
the cubic phase protected the selected peptide or protein from chemical and
physical degradation with its native confirmation and bioactivity retained.
Areas covered in this review: In this review, the literature pertaining to the
delivery of various bioactives from cubic liquid crystalline phases is examined,
with a particular focus on peptides and proteins. The scope and limitations
of the cubic phases in this respect and the future of cubic liquid crystalline
systems as sustained delivery systems are highlighted.
What the reader will gain: The reader will be able to gain an understanding
of the properties of the bicontinuous cubic phase and how its structural
attributes make these systems desirable for sustained delivery of bioactives,
in particular peptides and proteins, but also how these same structural properties
have hindered progress towards clinical applications. Current strategies
to overcome these issues will also be discussed.
Take home message: The bicontinuous cubic phase offers great potential in
the field of peptide and protein delivery, but limited research in this area
precludes definite conclusions to its future in this respect.
UR - https://www.scopus.com/pages/publications/77957044587
U2 - 10.1517/17425247.2010.515584
DO - 10.1517/17425247.2010.515584
M3 - Article
SN - 1742-5247
VL - 7
SP - 1133
EP - 1144
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 10
ER -